Your browser doesn't support javascript.
loading
Robotic Surgery for Malignant Liver Disease: a Systematic Review of Oncological and Surgical Outcomes.
Diaz-Nieto, Rafael; Vyas, Soumil; Sharma, Dinesh; Malik, Hassan; Fenwick, Stephen; Poston, Graeme.
Afiliación
  • Diaz-Nieto R; Hepatobiliary Surgery Unit, Aintree University Hospital, Longmoor Ln, L9 7AL, Liverpool, UK.
  • Vyas S; Division of HPB surgery, Surgical Gastroenterology and Surgical Oncology Sir H N Reliance Foundation Hospital, Mumbai, India.
  • Sharma D; HPB/Liver Transplant Surgery Unit, Royal Free Hospital, London, UK.
  • Malik H; Hepatobiliary Surgery Unit, Aintree University Hospital, Longmoor Ln, L9 7AL, Liverpool, UK.
  • Fenwick S; Hepatobiliary Surgery Unit, Aintree University Hospital, Longmoor Ln, L9 7AL, Liverpool, UK.
  • Poston G; Hepatobiliary Surgery Unit, Aintree University Hospital, Longmoor Ln, L9 7AL, Liverpool, UK.
Indian J Surg Oncol ; 11(4): 565-572, 2020 Dec.
Article en En | MEDLINE | ID: mdl-33281400
Robot-assisted laparoscopic surgery is yet another modification of minimally invasive liver surgery. It is described as feasible and safe from the surgical point of view; however, oncological outcomes need to be adequately analysed to justify the use of this technique when resecting malignant liver tumours. We reviewed existing English medical literature on robot-assisted laparoscopic liver surgery. We analysed surgical outcomes and oncological outcomes. We analysed operative parameters including operative time, type of hepatectomy, blood loss, conversion rate, morbidity and mortality rates and length of stay. We also analysed oncological outcomes including completeness of resection (R status), recurrence, survival and follow-up data. A total of 582 patients undergoing robot-assisted laparoscopic liver surgery were analysed from 17 eligible publications. Only 5 publications reported survival data. The overall morbidity was 19% with 0.2% reported mortality. R0 resection was achieved in 96% of patients. Robotic liver surgery is feasible and safe with acceptable morbidity and oncological outcomes including resection margins. However, well-designed trials are required to provide evidence in terms of survival and disease-free intervals when performed for malignancy.
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Systematic_reviews Idioma: En Revista: Indian J Surg Oncol Año: 2020 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Systematic_reviews Idioma: En Revista: Indian J Surg Oncol Año: 2020 Tipo del documento: Article